In human or murine triple-negative breast cancer cells treated with carboplatin, doxorubicin, gemcitabine, or paclitaxel, expression of CD47, CD73, and PDL1 changed in a HIF-dependent manner and consequently, increase in the ability of cancer cells to evade innate and adaptive immunity was observed [47]. The gene discussed is CD47; the disease is cancer.